Results 21 to 30 of about 39,319 (333)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Blood Advances, 2023
Key Points • One-third of patients with CLL relapsing on ibrutinib do not carry BTK/PLCG2 mutations, even with a 0.1% sensitivity.• Additional mechanisms, such as del(8p), EGR2 and NF-κB pathway mutations, may be cooperating in determining progression on
S. Bonfiglio, L. Sutton, V. Ljungström, A. Capasso, T. Pandzic, S. Weström, H. Foroughi-Asl, A. Skaftason, A. Gellerbring, Anna Lyander, F. Gandini, G. Gaidano, L. Trentin, L. Bonello, G. Reda, C. Bödör, N. Stavroyianni, C. Tam, R. Marasca, F. Forconi, P. Panayiotidis, I. Ringshausen, O. Jakšić, A. Frustaci, S. Iyengar, M. Coscia, S. Mulligan, L. Ysebaert, V. Strugov, C. Pavlovsky, R. Walewska, A. Österborg, D. Cortese, P. Ranghetti, P. Baliakas, K. Stamatopoulos, L. Scarfò, R. Rosenquist, P. Ghia   +38 more
semanticscholar   +1 more source

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Blood Advances, 2022
Key Points Long-term RESONATE-2 data show sustained PFS and OS benefits (medians not reached) for first-line ibrutinib treatment in patients with CLL. Forty-two percent of patients continued ibrutinib for up to 8 years; dose management for AEs allowed ...
P. Barr, C. Owen, T. Robak, A. Tedeschi, O. Bairey, J. Burger, P. Hillmen, S. Coutre, C. Dearden, S. Grosicki, H. McCarthy, Jian-yong Li, F. Offner, C. Moreno, Cathy Zhou, E. Hsu, A. Szoke, T. Kipps, P. Ghia   +18 more
semanticscholar   +1 more source

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood, 2022
Shanafelt et al report on the long-term outcome of the pivotal ECOG-ACRIN E1912 study, detailing the continued superiority of ibrutinib plus rituximab (IR) compared to the prior standard treatment—fludarabine, cyclophosphamide and rituximab (FCR)—for ...
T. Shanafelt, X. V. Wang, C. Hanson, E. Paietta, S. O'Brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman, N. Kay   +21 more
semanticscholar   +1 more source

Ibrutinib-induced cardiomyopathy [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2019
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic ...
Htay Htay Kyi, Yazan Zayed, Samer Al Hadidi   +2 more
openaire   +4 more sources

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia. [PDF]

EJHaem
ABSTRACT Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects. Methods We performed a retrospective analysis of venetoclax consolidation of 20 patients with CLL after initial BTKi discontinuation.
Heyman B, Choi M, Kipps TJ.
europepmc   +2 more sources

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood, 2022
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are ...
C. Tam, J. Allan, T. Siddiqi, T. Kipps, R. Jacobs, Stephen Samuel Opat, P. Barr, A. Tedeschi, L. Trentin, R. Bannerji, S. Jackson, B. Kuss, C. Moreno, E. Szafer-Glusman, K. Russell, Cathy Zhou, J. Ninomoto, J. Dean, W. Wierda, P. Ghia   +19 more
semanticscholar   +1 more source

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

Haematologica, 2020
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms
Damien Blez, Marion Blaize, Carole Soussain, Alexandre Boissonnas, Aïda Meghraoui-Kheddar, Natacha Menezes, Anaïs Portalier, Christophe Combadière, Véronique Leblond, David Ghez, Arnaud Fekkar   +10 more
doaj   +1 more source

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Journal of Clinical Oncology, 2023
PURPOSE In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL).
T. Munir, C. Moreno, C. Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, A. Osterborg, T. Robak, M. Šimkovič, D. Stevens, S. Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, C. Niemann, A. Kater   +24 more
semanticscholar   +1 more source

Efficacy in the margins of NHL with ibrutinib [PDF]

Blood, 2017
In this issue of Blood, Noy et al report on the efficacy of single-agent ibrutinib in patients with relapsed or refractory marginal zone lymphoma (MZL). They demonstrate an overall response rate of 48% and a median progression-free survival of 14 months, establishing the Bruton tyrosine kinase (BTK) inhibitor ibrutinib as a therapeutic option for this ...
Paul M. Barr
openalex   +4 more sources

Ibrutinib in hematoonkology [PDF]

Klinická farmakologie a farmacie, 2016
Poznani funkce B-buněcneho receptoru a jeho signalizacni kaskady umožnilo vývoj molekul, ktere inhibuji jednotlive enzymy teto drahy. Ibrutinib je inhibitor Brutonovy tyrozinkinazy, ktera ma klicove postaveni v přenosu signalu tohoto receptoru. V soucasne době je preparat registrovaný pro lecbu relabujici a refrakterni B-chronicke lymfocytarni leukemie,
Juraj Ďuraš, Roman Hájek, Michal Kaščák, Jana Zuchnická, Jana Mihalyova   +4 more
openaire   +2 more sources